Search clinical trials for: NeoCart

Total 535 results

M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Withdrawn

Autologous Stem Cell Transplants for Chronic Myelogenous Leukemia

Leukemia

United States
M.D. Anderson Cancer Center

Completed

Purged Circulating Tumor Cells (CTCs) From Metastatic Breast Cancer

Breast Cancer | Invasive Breast Carcinoma | Metastatic Breast Carcinoma

United States
Dana-Farber Cancer Institute
Pharmacyclics LLC.; The Leukemia and Lymphoma Society; Blood Cancer Research...

Active, not recruiting

A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia (iFCR)

Leukemia | Chronic Lymphocytic Leukemia

United States
Masonic Cancer Center, University of Minnesota
National Cancer Institute (NCI); National Institutes of Health (NIH)

Withdrawn

Treg Cells for AGVHD in Non-myeloablative UCB Transplant

Hematologic Malignancies

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); National Institutes of Health (NIH)

Withdrawn

Adoptive Therapy Using Antigen-Specific CD4 T-Cells

Melanoma | Sarcoma
M.D. Anderson Cancer Center
Intrexon Corporation

Terminated

Study of Adoptive Cellular Therapy Using Autologous T Cells Transduced With Lentivirus to Express a CD33 Specific Chimeric Antigen Receptor in Patients With Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia

Acute Myeloid Leukemia | Hematopoietic/Lymphoid Cancer

United States
National Heart, Lung, and Blood Institute (NHLBI)
GlaxoSmithKline; University of Virginia

Completed

Ofatumumab-based Induction Chemoimmunotherapy in Previously Untreated Patients With CLL/SLL

Small Lymphocytic Lymphoma | CLL (Chronic Lymphocytic Leukemia)

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Bone Marrow Transplantation in Treating Patients With Chronic Lymphocytic Leukemia

Leukemia

United States
Benjamin Tomlinson

Recruiting

Human AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies

Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Non Hodgkin Lymphoma

United States
UNC Lineberger Comprehensive Cancer Center
The V Foundation; Bellicum Pharmaceuticals

Recruiting

Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma

Immune System Diseases | Lymphoma | Lymphoma, B-Cell | Lymphatic Diseases | Immunoproliferative Disorders

United States
M.D. Anderson Cancer Center
SmithKline Beecham

Completed

TMC (Topotecan, Cyclophosphamide and Melphalan) for Multiple Myeloma

Myeloma

United States
UNC Lineberger Comprehensive Cancer Center
Bellicum Pharmaceuticals; University Cancer Research Fund at Lineberger Comprehensive...

Recruiting

Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC

Head and Neck Cancer | Relapse | Refractory Cancer | Recurrent

United States
M.D. Anderson Cancer Center

Completed

Busulfan and Fludarabine Followed by Post-transplant Cyclophosphamide

Lymphoma | Hematologic Diseases | Leukemia | Myeloma

United States
M.D. Anderson Cancer Center

Recruiting

Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances

B-Cell Lymphoma | Myelodysplastic Syndromes (MDS) | Acute Myeloid Leukemia (AML)

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
BioSante Pharmaceuticals; David H. Koch Charitable Foundation

Completed

A Neoadjuvant Study of Androgen Ablation Combined With Cyclophosphamide and GVAX Vaccine for Localized Prostate Cancer

Prostate Cancer Adenocarcinoma in Situ

United States
M.D. Anderson Cancer Center

Completed

Purine Analog-Based Conditioning in Patients With Severe Aplastic Anemia

Aplastic Anemia

United States
M.D. Anderson Cancer Center

Not yet recruiting

Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid Malignancies

Myeloid Malignancies | Lymphodepleting Chemotherapy

United States
M.D. Anderson Cancer Center
Bellicum Pharmaceuticals

Recruiting

Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)

Solid Tumors

United States
Steven E. Coutre
Bayer

Completed

Phase 2 Fludarabine, Cytoxan and FCCAM <Alemtuzumab> in Untreated B-Cell Chronic Lymphocytic Leukemia

Leukemia | Chronic Lymphocytic Leukemia (CLL) | Chronic Leukemia | B-cell Leukemia

United States
M.D. Anderson Cancer Center

Recruiting

Phase I/II Trial of Cord Blood-Derived NK Cells Genetically Engineered With NY-ESO-1 TCR/IL-15 Cell Receptor for Relapsed/Refractory Multiple Myeloma

Myeloma

United States
M.D. Anderson Cancer Center

Recruiting

Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma

Advanced Renal Cell Carcinoma | Advanced Mesothelioma | Advanced Osteosarcoma

United States
University of Illinois at Chicago

Terminated

Partially HLA Mismatched (Haploidentical) Allogeneic Bone Marrow Transplantation

Hematologic Malignancies

United States
M.D. Anderson Cancer Center
Genentech, Inc.

Completed

Fludarabine, Cyclophosphamide, and Rituximab - High Dose Frontline

Chronic Lymphocytic Leukemia

United States
M.D. Anderson Cancer Center
Bayer

Completed

Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia

United States
M.D. Anderson Cancer Center

Recruiting

Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1

Myxoid/Round Cell Liposarcoma | Synovial Sarcoma

United States
Emory University
Bristol-Myers Squibb; Brooklyn ImmunoTherapeutics, LLC

Withdrawn

Nivolumab & IRX-2 With Surgery for Resectable Stage III-IVA Oral Cavity Cancer or HPV-Positive Oropharyngeal Cancer

Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 | Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 | Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7 | Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma | Stage II Oral Cavity Squamous Cell...

United States
M.D. Anderson Cancer Center
Bayer

Completed

FCR Plus Sargramostim (GM-CSF) as Frontline Therapy for Symptomatic Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

United States
UNC Lineberger Comprehensive Cancer Center

Not yet recruiting

Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells

Ovarian Cancer | Epithelial Ovarian Cancer | Ovary Neoplasm | Recurrent

United States
Kiromic, Inc.

Terminated

Cyclophosphamide, TAPA-Pulsed Dendritic Cell Therapy and Imiquimod in Progressive and/or Refractory Solid Malignancies

Cancer | Progressive Solid Malignancies | Refractory Solid Malignancies

United States
M.D. Anderson Cancer Center
Biogen

Completed

Safety and Efficacy of 90Y Zevalin in Nonmyeloablative Transplantation for Lymphoid Malignancies

Lymphoma | Leukemia

United States
M.D. Anderson Cancer Center

Recruiting

Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignances

Hematological Malignancy

United States
M.D. Anderson Cancer Center

Completed

Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies

Chronic Lymphocytic Leukemia | Acute Lymphocytic Leukemia | B-Lymphoid Malignancies | Non-hodgkin Lymphoma

United States
M.D. Anderson Cancer Center
Astex Pharmaceuticals, Inc.; Pharmatech

Completed

Evaluation of the Safety and Efficacy of Nipent, Cytoxan, and Rituxan

Lymphoma

United States
C. Babis Andreadis
University of California, Davis

Recruiting

Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

Follicular Lymphoma | Burkitt Lymphoma | Mantle Cell Lymphoma | Lymphoplasmacytic Lymphoma | Diffuse Large B Cell Lymphoma | Refractory Non-Hodgkin Lymphoma | Small Lymphocytic Lymphoma | Primary Mediastinal Large B Cell Lymphoma | Transformed Lymphoma

United States
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI); Iovance Biotherapeutics, Inc.; The V Foundation...

Completed

Lymphodepletion Plus Adoptive Cell Therapy With High Dose IL-2 in Adolescent and Young Adult Patients With Soft Tissue Sarcoma

Sarcoma

United States
Dana-Farber Cancer Institute
Eisai Inc.

Active, not recruiting

A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer

Inflammatory Breast Cancer | Human Epidermal Growth Factor 2 Negative Carcinoma of Breast

United States
H. Lee Moffitt Cancer Center and Research Institute
Turnstone Biologics, Corp.

Recruiting

Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma

Metastatic Melanoma | Conjunctival Melanoma | Ocular Melanoma | Unresectable Melanoma | Uveal Melanoma | Cutaneous Melanoma | Mucosal Melanoma | Iris Melanoma | Acral Melanoma | Non-Cutaneous Melanoma

United States
Stanford University
National Cancer Institute (NCI); National Institutes of Health (NIH)

Suspended

CD34 Selected Allogeneic HCT w/ Myeloablative Conditioning Plus CD8+ Memory TCell Infusion in MDS, AL and CML

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Acute Lymphoblastic Leukemia | Chronic Myeloid Leukemia | Acute Leukemia

United States
Dana-Farber Cancer Institute

Completed

Cabozantinib With Topotecan-Cyclophosphamide

Refractory Ewing Sarcoma | Refractory Osteosarcoma | Relapsed Ewing Sarcoma | Relapsed Osteosarcoma

United States
M.D. Anderson Cancer Center
Bayer

Completed

CFAR Study in Patients With Chronic Lymphocytic Leukemia

Leukemia | Chronic Lymphocytic Leukemia

United States
M.D. Anderson Cancer Center
Millennium Pharmaceuticals, Inc.

Completed

Study of Bortezomib in Combination With Cyclophosphamide and Rituximab

Lymphoma | Mantle Cell Lymphoma

United States
M.D. Anderson Cancer Center

Completed

Non-Myeloablative Allogeneic Stem Cell Transplantation

Lymphoma

United States
Emory University
Celgene Corporation

Terminated

A Phase I Trial Using Cyclophosphamide, Rituximab and Revlimid (CR2) for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Small Lymphocytic Lymphoma (SLL)

Leukemia, Lymphocytic, Chronic, B-Cell | Chronic Lymphocytic Leukemia | Lymphoma, Small Lymphocytic

United States
National Cancer Institute (NCI)

Terminated

Chemotherapy Followed by Infusion of DMF5 Cells to Treat Metastatic Melanoma

Melanoma | Malignant Melanoma | Melanoma, Experimental

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Chronic Lymphocytic Leukemia

Leukemia

United States
M.D. Anderson Cancer Center

Completed

Safety and Efficacy of Campath in Nonmyeloablative Transplantation

Lymphoma | Leukemia

United States
NYU Langone Health
Millennium Pharmaceuticals, Inc.

Terminated

Chloroquine in Combination With VELCADE and Cyclophosphamide for Relapsed and Refractory Multiple Myeloma

Multiple Myeloma

United States
M.D. Anderson Cancer Center

Completed

Autologous Transplantation for Chronic Myelogenous Leukemia

Chronic Myelogenous Leukemia

United States
M.D. Anderson Cancer Center
Kite, A Gilead Company; Acerta Pharma, LLC

Recruiting

A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma

Lymphoma | Mantle Cell Lymphoma

United States
Fred Hutchinson Cancer Center
Lonza Walkersville, Inc.

Recruiting

Mesothelin-Specific T-Cells (FH-TCR-Tᴍsʟɴ) for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma

Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Ductal Adenocarcinoma

United States

Search clinical trials for: NeoCart

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Moldova

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations